From: Pharmaceutical prevention strategy for arteriovenous fistula and arteriovenous graft failure
Author | Design | N (Control) | Exposure Timing | Outcome (duration) | VAF development |
---|---|---|---|---|---|
Wanner et al [79] (4D study) | Placebo-controlled | 1255 (636) | Atorvastatin 20 mg/day | Incidence of cardiovascular events (4 years) | NA |
Fellstrom et al [78] (AURORA trial) | Placebo-controlled | 2776 (1385) | Rosuvastatin 10 mg/day Pre | Incidence of VA procedure (3.8 years) | Equivalent risk (RR 1.10, 95% CI 0.95–1.27, P = 0.19) |
Baigent et al [76] (SHARP trial) | Placebo-controlled | 9270 (4620) | Simvastatin 20 mg/day + Ezetimibe 10 mg/day Pre | Incidence of VA occulusive events (5 years) | Unclear (29.7% vs. 33.5%, RR 0.87, 95% CI 0.75–1.00, P = 0.05) |
Herrington et al [75] (Combined analysis of AURORA & SHARP trial) | Placebo-controlled | 1432 (725) | Rosuvastatin 10 mg/day or Simvastatin 20 mg/day + Ezetimibe 10 mg/day Pre | Incidence of VA occulusive events (4.5 years) | Equivalent risk (29.3% vs. 30.5%, RR 0.95, 95% CI 0.85–1.05, P = 0.29) |